HomeAM6 • FRA
add
Amicus Therapeutics, Inc.
Previous close
€8.40
Day range
€8.30 - €8.30
Year range
€7.85 - €11.10
Market cap
2.69B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 149.71M | 30.09% |
Operating expense | 118.90M | 10.66% |
Net income | 14.74M | 143.55% |
Net profit margin | 9.85 | 133.49% |
Earnings per share | 0.09 | 800.00% |
EBITDA | 18.01M | 1,292.85% |
Effective tax rate | -85.77% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 249.95M | -12.67% |
Total assets | 785.03M | 0.92% |
Total liabilities | 590.99M | -4.33% |
Total equity | 194.04M | — |
Shares outstanding | 300.12M | — |
Price to book | 12.92 | — |
Return on assets | 5.08% | — |
Return on capital | 6.33% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 14.74M | 143.55% |
Cash from operations | -3.92M | -213.24% |
Cash from investing | -20.39M | 14.88% |
Cash from financing | 1.10M | -86.64% |
Net change in cash | -20.10M | -24.14% |
Free cash flow | 8.65M | 215.80% |
About
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. Wikipedia
Founded
Feb 4, 2002
Website
Employees
499
